scholarly journals Expression of the Autoantigen Topoisomerase‐1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study

2020 ◽  
Vol 2 (11) ◽  
pp. 657-661
Author(s):  
Tricia R. Cottrell ◽  
Frederic Askin ◽  
Marc K. Halushka ◽  
Livia Casciola‐Rosen ◽  
Zsuzsanna H. McMahan
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Case Control Study ◽  
Case Control ◽  
Topoisomerase 1 ◽  
Control Study

scholarly journals Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study

2020 ◽  
Vol 202 (12) ◽  
pp. 1710-1713 ◽  
Author(s):  
Anthony J. Esposito ◽  
Aravind A. Menon ◽  
Auyon J. Ghosh ◽  
Rachel K. Putman ◽  
Laura E. Fredenburgh ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

scholarly journals Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study

2020 ◽  
Vol 9 (3) ◽  
pp. 700
Author(s):  
Quentin Gibiot ◽  
Isabelle Monnet ◽  
Pierre Levy ◽  
Anne-Laure Brun ◽  
Martine Antoine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Case Control Study ◽  
Standard Of Care ◽  
Case Control ◽  
Risk Of Death ◽  
Increased Risk ◽  
Two Factors ◽  
Control Study

Interstitial lung disease (ILD) seems to be associated with an increased risk of lung cancer (LC) and to have a poorer prognosis than LC without ILD. The frequency of ILD in an LC cohort and its prognosis implication need to be better elucidated. This retrospective, observational, cohort study evaluated the frequency of ILD among LC patients (LC–ILD) diagnosed over a 2-year period. LC–ILD patients’ characteristics were compared to those with LC without ILD (LC–noILD). Lastly, we conducted a case–control study within this cohort, matching three LC–noILDs to each LC–ILD patient, to evaluate the ILD impact on LC patients’ prognoses. Among 906 LC patients, 49 (5.4%) also had ILD. Comparing LC–ILD to LC–noILD patients, respectively, more were men (85.7% vs. 66.2%; p = 0.02); adenocarcinomas were less frequent (47.1% vs. 58.7%, p = 0.08); median [range] and overall survival was shorter: (9 [range: 0.1–39.4] vs. 17.5 [range: 0.8–50.4] months; p = 0.01). Multivariate analysis (hazard ratio [95% confidence interval]) retained two factors independently associated with LC risk of death: ILD (1.79 [1.22–2.62]; p = 0.003) and standard-of-care management (0.49 [0.33–0.72]; p < 0.001). Approximately 5% of patients with a new LC diagnosis had associated ILD. ILD was a major prognosis factor for LC and should be taken into consideration for LC management. Further studies are needed to determine the best therapeutic strategy for the LC–ILD population.

scholarly journals Association between ischaemic heart disease and interstitial lung disease: A case–control study

2009 ◽  
Vol 103 (4) ◽  
pp. 503-507 ◽  
Author(s):  
A. Ponnuswamy ◽  
R. Manikandan ◽  
A. Sabetpour ◽  
I.M. Keeping ◽  
J.P. Finnerty
Keyword(s):  
Heart Disease ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Ischaemic Heart Disease ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

scholarly journals What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 698
Author(s):  
Paresh Jobanputra ◽  
Feryal Malick ◽  
Emma Derrett-Smith ◽  
Tim Plant ◽  
Alex Richter
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Predictive Value ◽  
Case Control Study ◽  
Diagnostic Testing ◽  
Case Control ◽  
Trna Synthetase ◽  
Routine Practice ◽  
Nested Case Control ◽  
Control Study

Background:  It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.  The value of positive tests in low disease prevalence settings such as those tested in routine care is unknown.  We sought to determine the value of anti-Jo-1 auto-antibodies in routine practice. Methods: Our study was a nested case control study within a retrospective cohort of all patients tested for anti-ENA our hospital, from any hospital department, between January 2013 and December 2014.  Data was extracted from electronic records of anti-Jo-1 positive patients and randomly selected ENA negative patients (ratio of 1:2), allowing for a minimum follow up of at least 12 months after first testing. Results: 4009 samples (3581 patients) were tested.  Anti-ENA was positive in 616 (17.2%) patients, 40 (1.1%) were anti-Jo-1 positive. Repeat ENA testing was done for 350/3581 (9.8%) patients (428 of 4009 (10.7%) samples) and in 7/40 (17.5%) of anti-Jo-1 positive patients. The median interval between the first and second request was 124 days (inter-quartile range 233 days).  The frequencies of interstitial lung disease (ILD), myositis and Raynaud’s were comparable for anti-Jo-1 positive patients (n=40) and 80 randomly selected ENA negative controls.  Positive tests led to additional diagnostic testing in the absence of clinical disease.  Sensitivity of Jo-1 for ILD was 50% (CI 19-81%), specificity 68% (CI 59-77%), positive predictive value 12.5% (CI 4 to 27%) and negative predictive value 93.8% (CI 86-98%). Of 10 (25%) patients with high anti-Jo1 levels, 3 had ILD, one myositis and two a malignancy (disseminated melanoma and CML).  Conclusion: Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD.  Repeated test requests were common and potentially unnecessary indicating that controls over repeat requests could yield significant cost savings.

Sign in / Sign up

Export Citation Format

Share Document